Search

• GSK welcomes key agreement to support global preparedness against pandemic influenza

  Media

  GSK welcomes agreement reached at OEWG coordinated by WHO on a Framework to support global preparedness for a future influenza pandemic.

  https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-key-agreement-to-support-global-preparedness-against-pandemic-influenza/

  First published: 18 April 2011

• Emergence of a new H1N1 influenza A strain (swine influenza)

  Media

  GSK is closely monitoring H1N1 strain in Mexico, US, Canada, France, Spain & New Zealand. WHO stated, situation a cause for concern.

  https://www.gsk.com/en-gb/media/press-releases/emergence-of-a-new-h1n1-influenza-a-strain-swine-influenza/

  First published: 26 April 2009

• ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV

  Media

  ViiV Healthcare announced results from phase III BRIGHTE study of fostemsavir

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv/

  First published: 27 October 2017

• ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir at 48 weeks in heavily treatment-experienced patients with HIV

  Media

  BRIGHTE study highlights ViiV Healthcare’s commitment to developing innovative medicines for all people living with HIV

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-at-48-weeks-in-heavily-treatment-experienced-patients-with-hiv/

  First published: 31 October 2018

• ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

  Media

  ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-regulatory-application-to-the-european-medicines-agency-for-fostemsavir/

  First published: 10 January 2020

• ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting, injectable treatment regimen in adults living with HIV-1

  Media

  ViiV Healthcare presents positive long-term data from phase III study

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-long-term-data-from-phase-iii-study-demonstrating-efficacy-and-safety-of-cabotegravir-and-rilpivirine/

  First published: 09 March 2020

• ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy

  Media

  ViiV announced the start of a phase III clinical trial for the safety and efficacy of dolutegravir&rilpivirine for adult patients with HIV.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-begins-phase-iii-programme-with-dolutegravirrilpivirine-combination-for-hiv-maintenance-therapy/

  First published: 06 May 2015

• ViiV Healthcare presents positive new findings from two studies of its investigational, long-acting regimen of cabotegravir and rilpivirine, including five-year data showing long-term durability, efficacy, safety, and tolerability

  Media

  Positive new findings from two studies of the investigational, long-acting regimen of cabotegravir and rilpivirine for treatment of HIV.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-new-findings-from-two-studies-of-its-investigational-long-acting-regimen-of-cabotegravir-and-rilpivirine/

  First published: 22 October 2020

• ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018

  Media

  Juluca, the first 2-drug regimen, once daily, single pill regimen, maintains viral suppression through 100 weeks.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolutegravirrilpivirine-at-aids-2018/

  First published: 24 July 2018

• ViiV Healthcare presents positive, 48-week data from two pivotal phase III studies showing long-acting, injectable two-drug regimen of cabotegravir and rilpivirine has similar efficacy to daily, three-drug oral treatment in adults living with HIV-1 infection

  Media

  Comprehensive data from ATLAS and FLAIR studies presented today at the 2019 Conference on Retroviruses and Opportunistic Infections

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-48-week-data-from-two-pivotal-phase-iii-studies/

  First published: 07 March 2019